Watch CBSN Live

Once-Yearly Drug Prevents Fractures

bisphosphonates -- is that they aren't easy to take the right way.
They have to be taken first thing in the morning, on an empty stomach, 30
minutes before eating anything -- and you have to remain standing or sitting
upright during this half-hour fast.

That's why only 30% of people are still taking their osteoporosis drugs
after a year, says study leader Dennis M. Black, PhD, of the University of
California, San Francisco.

"And who knows how many of that 30% are actually taking it right,"
Black tells WebMD. "So in terms of clinical effect, even if our study shows
Reclast is just the same as some other osteoporosis drugs, the real clinical
effect will be better."

The study did not actually compare Reclast to other osteoporosis drugs,
notes study investigator and osteoporosis specialist Felicia Cosman, MD, of
Helen Hayes Hospital and Columbia University. Cosman also serves as clinical
director for the National Osteoporosis Foundation.

"The results from this placebo-controlled trial really show that Reclast
is at least as effective vs. fractures -- if not more effective -- than
anything else in this drug class we currently have on the market," Cosman
tells WebMD.

Reclast doesn't totally prevent fractures. Over three years, 3.3% of women
who took the drug had vertebral fractures and 1.4% had hip fractures. But that
was far better than the 10.9% rate of vertebral fractures and the 2.5% rate of
hip fractures in the placebo group.

"We want to stress that in between these infusions, women still need to
take their calcium and vitamin D and exercise and use all the lifestyle
measures that should be done to reduce bone loss. This would not take the place
of that," Cosman warns.

Women tolerated the annual 15-minute infusions very well. After the
infusion, about 14% of patients had some symptoms of what doctors call an acute
phase reaction. They felt as though they had a mild viral infection, with
low-grade fever, muscle and joint aches, and/or headache. In no case did this
last longer than three days, Cosman says.

Women who took Reclast also had a significantly higher rate of serious
atrial fibrillation -- a dangerous, abnormal heart rhythm. This happened to 50
of the 3,889 women who received the drug.

Black, Cosman, and colleagues report their findings in the May 3 issue of
the New England Journal of Medicine. An editorial by Juliet Compston,
MD, professor of bone medicine at the University of Cambridge, England,
accompanies the study.

Compston says that Reclast will be appropriate for any woman whose bone
density puts her at high risk of fracture.

"We have an exciting new option which is at least as effective as other
options in reducing fractures," Compston tells WebMD. "It has something
which many will see as an advantage: It has to be taken only once a year --
although the intravenous infusion will be a consideration for some. It is a new
first-line treatment for osteoporosis."

The FDA currently approves Reclast for the treatment of Paget's disease, a
metabolic bone disorder. Novartis Pharmaceutical's application to approve
Reclast for postmenopausal osteoporosis is currently under FDA review. Novartis
funded the Black study.

By Daniel DeNoon
Reviewed by Louise Chang
B)2005-2006 WebMD, Inc. All rights reserved

View CBS News In
CBS News App Open
Chrome Safari Continue
Be the first to know
Get browser notifications for breaking news, live events, and exclusive reporting.